Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$0.46
$0.43
$0.19
$1.24
$16.71M1.85661,416 shs351,642 shs
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$0.60
$0.67
$0.46
$3.07
$15.91MN/AN/A3,009 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$0.36
+2.9%
$0.94
$0.32
$8.17
$3.71M1.58176,325 shs63,965 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$0.48
+4.4%
$0.53
$0.40
$1.09
$574.33M-0.681.72 million shs1.10 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00%0.00%0.00%0.00%+0.22%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.00%0.00%0.00%0.00%-12.73%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
+2.11%-3.64%-61.60%-75.00%-90.81%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-55.36%-99.22%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
+3.67%-6.47%-10.17%-20.10%-3.64%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
2.0982 of 5 stars
3.55.00.00.02.40.00.0
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
3.00
Buy$17.254,725.17% Upside
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$48.34M0.35N/AN/A$0.48 per share0.95
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$110K144.65N/AN/A$0.20 per share3.00
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A$0.01 per shareN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$1.93M297.58N/AN/A($0.06) per share-7.95

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
-$23.29M-$1.20N/AN/A-47.03%-113.57%-38.22%N/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
-$9.14MN/A0.00N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$51.60M-$6.00N/AN/AN/A-433.08%-146.39%5/10/2024 (Estimated)
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
-$62.60M-$0.06N/AN/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)

Latest MBIO, CEMI, NEPT, CYAD, and NWBO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/11/2024Q4 2023
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$1.68-$0.71+$0.97-$0.71N/AN/A
3/5/2024Q4 2023
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A-$0.02-$0.02-$0.02N/A$0.45 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/A
1.23
1.04
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
0.74
0.74
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A
0.09
0.09

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
33736.73 million35.51 millionNot Optionable
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
9526.52 million26.28 millionNot Optionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
8010.39 million10.17 millionNot Optionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
251.20 billion1.09 billionNot Optionable

MBIO, CEMI, NEPT, CYAD, and NWBO Headlines

SourceHeadline
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.65Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.65
americanbankingnews.com - April 24 at 4:06 AM
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67
americanbankingnews.com - April 16 at 3:34 AM
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
prnewswire.com - March 21 at 11:09 AM
‘Spoofing’ case might draw back curtain on high-speed trading firms‘Spoofing’ case might draw back curtain on high-speed trading firms
ft.com - March 2 at 10:11 AM
Northwest Biotherapeutics, Inc. (NWBO)Northwest Biotherapeutics, Inc. (NWBO)
uk.finance.yahoo.com - February 29 at 2:53 PM
Northwest Biotherapeutics Stock (OTC:NWBO), Short Interest ReportNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest Report
benzinga.com - February 23 at 12:07 AM
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
finance.yahoo.com - February 7 at 4:37 PM
Northwest Biotherapeutics submits marketing application to UK MHRA for DCVax-LNorthwest Biotherapeutics submits marketing application to UK MHRA for DCVax-L
msn.com - December 22 at 10:28 AM
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For GlioblastomaNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma
finanznachrichten.de - December 21 at 12:53 PM
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For GlioblastomaNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
finance.yahoo.com - December 21 at 12:53 PM
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization ApplicationNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
finance.yahoo.com - November 22 at 2:22 PM
Northwest Biotherapeutics Inc NWBONorthwest Biotherapeutics Inc NWBO
morningstar.com - October 31 at 12:12 PM
Northwest Bio: Another Small Filing DelayNorthwest Bio: Another Small Filing Delay
msn.com - October 14 at 10:44 AM
NW Bio dips on announcing delay in submission of marketing application for DCVaxNW Bio dips on announcing delay in submission of marketing application for DCVax
seekingalpha.com - October 13 at 12:56 PM
Northwest Biotherapeutics Shares Slide on Application DelayNorthwest Biotherapeutics Shares Slide on Application Delay
marketwatch.com - October 13 at 12:56 PM
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization ApplicationNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
finance.yahoo.com - October 13 at 12:56 PM
Police searching for suspects in Northwest DC shootingPolice searching for suspects in Northwest DC shooting
wjla.com - October 10 at 10:28 AM
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Companys Scientific Advisory BoardNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
finance.yahoo.com - September 12 at 6:48 PM
Sports Betting In The Northwest Territories- Is it Legal? Best Sportsbooks In The NWTSports Betting In The Northwest Territories- Is it Legal? Best Sportsbooks In The NWT
basketballinsiders.com - August 30 at 6:42 PM
Northwest Bio: Is There Ever Going To Be A Right Time?Northwest Bio: Is There Ever Going To Be A Right Time?
msn.com - August 17 at 9:29 PM
Northwest Missouri State UniversityNorthwest Missouri State University
usnews.com - August 6 at 5:59 PM
Northwest HospitalNorthwest Hospital
health.usnews.com - August 4 at 6:51 PM
Standing Stone Circles: The most ancient builders of Northwest ArabiaStanding Stone Circles: The most ancient builders of Northwest Arabia
nationalgeographic.com - August 3 at 8:41 AM
Siloam Springs NewsSiloam Springs News
nwaonline.com - July 22 at 1:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chembio Diagnostics logo

Chembio Diagnostics

NASDAQ:CEMI
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.
Celyad Oncology logo

Celyad Oncology

NASDAQ:CYAD
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Mustang Bio logo

Mustang Bio

NASDAQ:MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Northwest Biotherapeutics logo

Northwest Biotherapeutics

OTCMKTS:NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.